EGFR and neoplasm: For patients with more than three tumor metastases, the median PFS were 11.3 months (95% CI, 3.1–22.9 months) and 15.1 months (95% CI, 8.1–22.2 months) (p = 0.874) (Figure 3) for the MWA plus EGFR-TKIs group and the EGFR-TKIs group, respectively, and the corresponding OS were 28.4 months (95% CI, 18.1–38.6 months) and 18.2 months (95% CI, 15.1–21.2 months) (p = 0.859), respectively (Figure 4).